"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"

This multicenter, non-randomized interventional study aims to assess coronary artery disease progression over 5 years in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), using coronary computed tomography angiography (CCTA). The primary endpoint is the visual evaluation of coronary stenosis using CAD-RADS v2.0, identifying changes between baseline (2018-2022) and study inclusion. The study will enroll 300 patients (100 protected, 200 non-protected) from La Pitié-Salpêtrière hospital and Saint Antoine Hospital (Paris). Participation lasts up to one week. Total study duration is 2 years, with extended follow-up through routine care data over 10 years.

NCT Number	NCT07427472
Lead Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions	Heterozygous Familial Hypercholesterolemia (HeFH)
Enrollment	300 participants
Start Date	2026-06-19
Primary Completion	2028-06-19 (estimated)
Study Completion	2036-06-19 (estimated)
Updated on ClinicalTrials.gov	2026-06-24